Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, non-randomized and single-center phase II clinical study,
to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib
in patients with Radioactive Iodine-refractory Differentiated Thyroid Cancer (RAIR-DTC).